Condition
    Effectiveness 2/5

    Ashwagandha for Dissociation

    Ashwagandha has no direct evidence in dissociation, and it should not be positioned as a treatment for it. What it has is moderate evidence for reducing subjective stress and anxiety scores and modestly lowering cortisol in stressed adults — which touches the anxiety and hyperarousal that frequently precede dissociative episodes. That indirect route is the entire case. Dissociation is driven by trauma, panic, sleep deprivation, and cannabis, and it responds to grounding techniques and trauma-focused therapy. An adaptogen that slightly reduces baseline anxiety may lower episode frequency for some people, but it treats none of the underlying mechanism and must never substitute for proper assessment.

    Overview

    Ashwagandha has no direct evidence in dissociation, and it should not be positioned as a treatment for it. What it has is moderate evidence for reducing subjective stress and anxiety scores and modestly lowering cortisol in stressed adults — which touches the anxiety and hyperarousal that frequently precede dissociative episodes. That indirect route is the entire case. Dissociation is driven by trauma, panic, sleep deprivation, and cannabis, and it responds to grounding techniques and trauma-focused therapy. An adaptogen that slightly reduces baseline anxiety may lower episode frequency for some people, but it treats none of the underlying mechanism and must never substitute for proper assessment.

    Verdict

    Insufficient evidence

    No dissociation-specific evidence at all; only an indirect anxiety-reduction rationale. Grounding skills and trauma-focused therapy are what actually work.

    How It Works

    Ashwagandha (Withania somnifera) appears to modulate the hypothalamic-pituitary-adrenal axis, reducing cortisol output under stress, and has GABAergic activity in preclinical models that may contribute to its anxiolytic and mild sedative effects. Since panic and acute anxiety are among the most common immediate triggers of depersonalization and derealization, lowering baseline anxious arousal is a plausible upstream lever. It has no known effect on the trauma processing, memory integration, or dissociative mechanisms themselves.

    Dosing & Protocol

    Typical dose

    Recommended dose
    300–600 mg standardized extract (5% withanolides) daily, if used at all
    Expected timeframe
    Any anxiety-mediated benefit emerges over 4–8 weeks; it does nothing during an acute episode

    Protocol

    notes
    Choose KSM-66 or Sensoril standardized extracts; raw root powder doses used in traditional practice are far higher and less studied
    dosage
    300–600 mg of a standardized extract daily, taken with food; some prefer evening dosing for its mild sedative effect
    duration
    8–12 weeks to assess any effect on baseline anxiety; not an acute rescue tool

    Evidence

    What the studies say

    Multiple randomized placebo-controlled trials in stressed but otherwise healthy adults show ashwagandha reduces perceived stress scale and anxiety inventory scores, with a frequently cited 2019 trial finding significant reductions in stress and morning cortisol at 240 to 600 mg daily over 60 days. A 2021 systematic review rated the anxiety evidence as promising but limited by small samples, short durations, and heterogeneous preparations. There are zero trials in dissociation, depersonalization, or derealization. By contrast, trauma-focused psychotherapies including EMDR and trauma-focused CBT have substantial randomized evidence for dissociative symptoms in PTSD.

    Dual impact of Ashwagandha: Significant cortisol reduction but no effects on perceived stress - A systematic review and meta-analysis

    Score: 8/10
    2025
    meta_analysis
    n=488

    Albalawi A, et al.

    The disconnect between cortisol and PSS outcomes highlights the need for longer treatment duration and broader demographic inclusion.

    View source

    Safety

    Caveats

    The central caveat is displacement: using a supplement while avoiding assessment allows treatable trauma, PTSD, panic disorder, or depression to continue untreated, and misses medical mimics such as temporal lobe epilepsy that require exclusion. Ashwagandha carries real safety considerations — case reports of liver injury exist, it can stimulate thyroid hormone output (relevant in hyperthyroidism), it may interact with sedatives and immunosuppressants, and it is not recommended in pregnancy. Its mild sedation can also blunt the alertness that grounding practice requires.

    Less likely to help if

    Anyone with active trauma symptoms, PTSD, or panic disorder who has not started evidence-based therapy. People whose dissociation is driven by cannabis or sleep deprivation, where removing the cause is dramatically more effective. Those with thyroid disease, liver conditions, or on sedating medication. And anyone hoping for acute relief during an episode, which this cannot provide.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.